Overview

* Balchem ( BCPC ) fiscal Q2 net sales rise 9.1% yr/yr, beating analyst expectations

* Adjusted EBITDA for fiscal Q2 grows 11.2% yr/yr, reaching $69.2 mln

* Co plans $36 mln facility in NY to expand micro-encapsulation capacity

Outlook

* Balchem ( BCPC ) plans new facility to expand micro-encapsulation capacity

* Company sees European anti-dumping duties as positive market development

Result Drivers

* HUMAN NUTRITION GROWTH - Driven by higher sales in food ingredients and solutions, and nutrients, contributing to record segment sales

* ANIMAL NUTRITION INCREASE - Higher sales in ruminant and monogastric species markets boosted segment performance

* SPECIALTY PRODUCTS RISE - Growth in performance gases and plant nutrition businesses led to record sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $255.50 $250.30

mln mln (3

Analysts

)

Q2 EPS $1.17

Q2 Net $38.30

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the specialty chemicals peer group is "buy"

* Wall Street's median 12-month price target for Balchem Corp ( BCPC ) is $192.00, about 20.8% above its July 30 closing price of $152.09

* The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)